How times a day do you take this medicine?
What is Paclitaxel Ebewe?
Paclitaxel Ebewe injection is used to treat advanced cancer of the ovaries, breast, non-small cell lung cancer, and Kaposi sarcoma. Kaposi sarcoma is a cancer of the skin and mucous membranes that is commonly found in patients with acquired immunodeficiency syndrome (AIDS).
Paclitaxel Ebewe belongs to the group of medicines called antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected, other unwanted effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects may not be serious but may cause concern. Some effects may not occur until months or years after the medicine is used.
Before you begin treatment with Paclitaxel Ebewe, you and your doctor should talk about the good Paclitaxel Ebewe will do as well as the risks of using it.
Paclitaxel Ebewe is to be administered only by or under the immediate supervision of your doctor.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Paclitaxel Ebewe is used in certain patients with the following medical conditions:
- Cancer of the bladder.
- Cancer of the cervix.
- Cancer of the endometrium.
- Cancer of the esophagus.
- Cancer of the fallopian tube or lining of the abdomen (spreading from the ovary).
- Cancers of the head and neck.
- Cancer of the prostate.
- Cancer of the stomach
- Cancer of the testes.
- Cancer of unknown primary site.
- Small cell lung cancer (a certain type found in the tissues of the lungs).
Paclitaxel Ebewe indications
As 1st-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As 1st-line therapy, Paclitaxel Ebewe is indicated in combination with cisplatin. In noncomparative trials, continuous infusion of Paclitaxel Ebewe 110-300 mg/m2 over 3-96 hrs every 3-4 weeks produced complete or partial response in 16-48% of patients with ovarian cancer and 25-61.5% of patients with metastatic breast cancer, many of whom were refractory to treatment with cisplatin or doxorubicin. About 23-100% of patients with ovarian cancer achieved complete or partial response with Paclitaxel Ebewe in combination with cisplatin, carboplatin, cyclophosphamide, altretamine and/or doxorubicin. Similarly, response rates of 30-100% were observed with Paclitaxel Ebewe plus doxorubicin, cisplatin, mitoxantrone and/or cyclophosphamide in patients with metastatic breast cancer. In several comparative trials, treatment with Paclitaxel Ebewe in patients with advanced ovarian cancer produced greater response rates than hydroxyurea (71% vs 0%) or cyclophosphamide (when both agents were combined with cisplatin; 79% vs 63%).
Adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial of Paclitaxel Ebewe, there was an overall favourable effect on disease-free and overall survival in the total population of patients with receptor-positive and -negative tumors, but the benefit has been specifically demonstrated only in patients with estrogen and progesterone receptor-negative tumours.
Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Paclitaxel Ebewe therapy in combination with cisplatin is indicated for the 1st-line treatment of advanced nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
Paclitaxel Ebewe is also indicated as a 2nd-line treatment of AIDS-related Kaposi's sarcoma.
Paclitaxel Ebewe is also found to be effective in patients with head and neck cancer, germ cell cancer, urothelial cancer, oesophageal cancer and non-Hodgkin's lymphoma.
How should I use Paclitaxel Ebewe?
Use Paclitaxel Ebewe as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Paclitaxel Ebewe. Talk to your pharmacist if you have questions about this information.
- Paclitaxel Ebewe is usually given as an injection at your doctor's office, hospital, or clinic. Contact your health care provider if you have any questions.
- If nausea, vomiting, diarrhea, or loss of appetite occurs, do not discontinue your medicine. Ask your doctor or pharmacist for ways to lessen these effects.
- You should receive certain other medicines, such as corticosteroids (eg, prednisone), diphenhydramine, and H blocker (eg, famotidine), before each treatment with Paclitaxel Ebewe to decrease the chance of an allergic reaction. Discuss any questions with your doctor.
- Wear gloves while handling Paclitaxel Ebewe.
- If you get Paclitaxel Ebewe on your skin, rinse the area thoroughly with soap and water. If you get Paclitaxel Ebewe in your eyes, nose, or mouth, flush the area thoroughly with water.
- If you miss a dose of Paclitaxel Ebewe, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Paclitaxel Ebewe.
Uses of Paclitaxel Ebewe in details
This medication is used to treat certain cancers (including breast, lung, and pancreatic cancer). Paclitaxel Ebewe belongs to a class of drugs known as chemotherapy drugs. It works by slowing or stopping the growth of cancer cells.
How to use Paclitaxel Ebewe intravenous
Read the Patient Information Leaflet available from your pharmacist before you start using Paclitaxel Ebewe. If you have any questions, consult your doctor or pharmacist.
This medication is given by injection into a vein by a health care professional. It is given on a schedule as directed by your doctor. Dosage is based on your medical condition, body size, laboratory tests, and response to treatment.
Paclitaxel Ebewe description
Paclitaxel Ebewe Injection Concentrate is a sterile solution containing 6 mg/mL Paclitaxel Ebewe, 2 mg/mL Anhydrous Citric Acid BP, 527 mg/mL PEG 35 Castor Oil and Ethanol BP.
Paclitaxel Ebewe is extremely hydrophobic, and is therefore formulated in PEG 35 castor oil and ethanol.
Paclitaxel Ebewe is an anticancer agent from the taxane class of drugs. It is a white powder with a molecular weight (MW) of 853.9. The CAS number for Paclitaxel Ebewe is 33069-62-4.
Paclitaxel Ebewe Injection Concentrate must be diluted prior to intravenous infusion.
Paclitaxel Ebewe is described chemically as (2 S,5 R,7 S,10 R,13 S)-10,20-bis(acetoxy)-2-benzoyloxy-1,7- dihydroxy-9-oxo-5,20- epoxytax-11-en-13-yl (3 S)-3-benzoylamino-3-phenyl-D-lactate.
Paclitaxel Ebewe Injection Concentrate has a pH of 6 to 7.
Paclitaxel Ebewe dosage
All patients should be premedicated prior to Paclitaxel Ebewe administration in order to minimize severe hypersensitivity reaction. Such premedication may consist of dexamethasone 20 mg orally approximately 12 and 6 hrs before Paclitaxel Ebewe, dipenhydramine (or its equivalent) 50 mg IV 30-60 min prior to Paclitaxel Ebewe, and cimetidine 300 mg or ranitidine 50 mg IV 30-60 min before Paclitaxel Ebewe.
Ovarian Carcinoma: Paclitaxel Ebewe administered IV over 3 hrs at a dose of 175 mg/m2 followed by cisplatin at a dose of 75 mg/m2, every 3 weeks. Paclitaxel Ebewe should be administered before cisplatin.
Paclitaxel Ebewe at a dose of 175 mg/m2 administered IV over 3 hrs every 3 weeks has been shown to be effective in patients with metastatic carcinoma of the ovary who have failed standard therapy.
Breast Carcinoma: Paclitaxel Ebewe at a dose of 175 mg/m2 administered IV over 3 hrs every 3 weeks has been shown to be effective in patients with metastatic carcinoma of the breast who have failed standard therapy.
For the adjuvant treatment of node-positive breast cancer, the recommended regimen is Paclitaxel Ebewe, at a dose of 175 mg/m2 IV over 3 hrs every 3 weeks for 4 courses administered sequentially to doxorubicin-containing combination chemotherapy.
When used in combination with trastuzumab, the recommended dose of Paclitaxel Ebewe is 175 mg/m2 administered IV over a period of 3 hrs with a 3-week interval between courses. Paclitaxel Ebewe may be started the day following the 1st dose of trastuzumab or immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.
Lung Carcinoma: Paclitaxel Ebewe administered IV over 3 hrs at a dose of 175 mg/m2 followed by cisplatin at a dose of 80 mg/m2, every 3 weeks.
Gastric Carcinoma: Paclitaxel Ebewe administered IV over 3 hrs at a dose of 175-210 mg/m2, and then it should be taken a rest at least 3 weeks. Determination of dosage should be considered by the age and symptoms. Single courses of Paclitaxel Ebewe should not be repeated until the neutrophil count is at least 1500 cell/mm3 and the platelet count is at least 100,000 cells/mm3. Patients who experience severe neutropenia (neutrophile <500 cells/mm3, for 7 days) or severe peripheral neuropathy during Paclitaxel Ebewe therapy should have the dosage reduced by 20% for subsequent courses of Paclitaxel Ebewe.
Administration: Paclitaxel Ebewe for injection must be diluted prior to infusion. Paclitaxel Ebewe should be diluted in 0.9% sodium chloride injection, 5% dextrose injection, 5% dextrose and 0.9% sodium chloride injection, or 5% dextrose in ringer's injection to a final concentration of 0.3-1.2 mg/mL. The solutions are physically and chemically stable for up to 27 hrs at ambient temperature (15-30°C). Upon preparation, solutions may show haziness, which is attributed to the formulation vehicle. No significant loss in potency has been noted following simulated delivery of the solution through IV tubing containing an in-line (0.22 micron) filter.
Paclitaxel Ebewe interactions
Interactions with Other Medicines: Cisplatin: Administration of cisplatin prior to Paclitaxel Ebewe treatment leads to greater myelosuppression than that seen when Paclitaxel Ebewe is given prior to cisplatin. In patients receiving cisplatin prior to Paclitaxel Ebewe, there is about a 33% decrease in Paclitaxel Ebewe clearance.
Ketoconazole: As ketoconazole may inhibit the metabolism of Paclitaxel Ebewe, patients receiving Paclitaxel Ebewe and ketoconazole should be closely monitored or the combination of these drugs should be avoided.
Doxorubicin: Sequence effects characterised by more profound neutropenic and stomatitis episodes have been observed with combination use of Paclitaxel Ebewe and doxorubicin when Paclitaxel Ebewe was administered before doxorubicin and using longer than recommended infusion times (Paclitaxel Ebewe administered over 24 hours; doxorubicin over 48 hours). Plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when Paclitaxel Ebewe and doxorubicin are used in combination. However, data from a trial using bolus doxorubicin and 3 hour Paclitaxel Ebewe infusion found no sequence effects on the pattern of toxicity.
Drugs Metabolised in the Liver: Caution should be exercised during concurrent administration of drugs which are metabolised in the liver (e.g. erythromycin) as such drugs may inhibit the metabolism of Paclitaxel Ebewe. The metabolism of Paclitaxel Ebewe is catalysed by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. In the absence of formal clinical drug interaction studies caution should be exercised when administering Paclitaxel Ebewe Injection Concentrate concomitantly with known substrates or inhibitors of these isoenzymes. In the clinical trial of Paclitaxel Ebewe in combination with trastuzumab (Herceptin), mean serum trough concentrations of trastuzumab were consistently elevated 1.5 fold as compared with serum concentrations of trastuzumab in combination with anthracycline plus cyclophosphamide (AC). Arthralgia or myalgia adverse events of Paclitaxel Ebewe appear to be of a higher incidence in patients being treated concurrently with filgrastim (granulocyte colony stimulating factor; G-CSF).
Paclitaxel Ebewe side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The most common adverse reactions ( ≥ 20%) with single-agent use of Paclitaxel Ebewe in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea.
The most common adverse reactions ( ≥ 20%) of Paclitaxel Ebewe in combination with carboplatin for non-small cell lung cancer are anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea, and fatigue. The most common serious adverse reactions of Paclitaxel Ebewe in combination with carboplatin for non-small cell lung cancer are anemia (4%) and pneumonia (3%). The most common adverse reactions resulting in permanent discontinuation of Paclitaxel Ebewe are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%). The most common adverse reactions resulting in dose reduction of Paclitaxel Ebewe are neutropenia (24%), thrombocytopenia (13%), and anemia (6%). The most common adverse reactions leading to withholding or delay in Paclitaxel Ebewe dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%).
In a randomized open-label trial of Paclitaxel Ebewe in combination with gemcitabine for pancreatic adenocarcinoma, the most common ( ≥ 20%) selected (with a ≥ 5% higher incidence) adverse reactions of Paclitaxel Ebewe are neutropenia, fatigue, peripheral neuropathy, nausea, alopecia, peripheral edema, diarrhea, pyrexia, vomiting, decreased appetite, rash, and dehydration. The most common serious adverse reactions of Paclitaxel Ebewe (with a ≥ 1% higher incidence) are pyrexia (6%), dehydration (5%), pneumonia (4%) and vomiting (4%). The most common adverse reactions resulting in permanent discontinuation of Paclitaxel Ebewe are peripheral neuropathy (8%), fatigue (4%) and thrombocytopenia (2%). The most common adverse reactions resulting in dose reduction of Paclitaxel Ebewe are neutropenia (10%) and peripheral neuropathy (6%). The most common adverse reactions leading to withholding or delay in Paclitaxel Ebewe dosing are neutropenia (16%), thrombocytopenia (12%), fatigue (8%), peripheral neuropathy (15%), anemia (5%) and diarrhea (5%).
Clinical Trials Experience In Metastatic Breast Cancer
Table 6 shows the frequency of important adverse events in the randomized comparative trial for the patients who received either single-agent Paclitaxel Ebewe or Paclitaxel Ebewe injection for the treatment of metastatic breast cancer.
Table 6: Frequencya of Important Treatment Emergent Adverse Events in the Randomized Metastatic Breast Cancer Study on an Every-3-Weeks Schedule
|Percent of Patients|
|ABRAXANE260 mg/m² over 30 min |
|Paclitaxel Ebewe Injection175 mg/m² over 3 h Urinary tract infections includes the preferred terms of: urinary tract infection, cystitis, urosepsis, urinary tract infection bacterial, and urinary tract infection enterococcal.|
Additional clinically relevant adverse reactions that were reported in < 10% of the patients with adenocarcinoma of the pancreas who received Paclitaxel Ebewe/gemcitabine included:
Infections & infestations: oral candidiasis, pneumonia
Vascular disorders: hypertension
Cardiac disorders: tachycardia, congestive cardiac failure
Eye disorders: cystoid macular edema
Grade 3 peripheral neuropathy occurred in 17% of patients who received Paclitaxel Ebewe/gemcitabine compared to 1% of patients who received gemcitabine only; no patients developed grade 4 peripheral neuropathy. The median time to first occurrence of Grade 3 peripheral neuropathy in the Paclitaxel Ebewe arm was 140 days. Upon suspension of Paclitaxel Ebewe dosing, the median time to improvement from Grade 3 peripheral neuropathy to ≤ Grade 1 was 29 days. Of Paclitaxel Ebewe-treated patients with Grade 3 peripheral neuropathy, 44% resumed Paclitaxel Ebewe at a reduced dose.
Sepsis occurred in 5% of patients who received Paclitaxel Ebewe/gemcitabine compared to 2% of patients who received gemcitabine alone. Sepsis occurred both in patients with and without neutropenia. Risk factors for sepsis included biliary obstruction or presence of biliary stent.
Pneumonitis occurred in 4% of patients who received Paclitaxel Ebewe/gemcitabine compared to 1% of patients who received gemcitabine alone. Two of 17 patients in the Paclitaxel Ebewe arm with pneumonitis died.
Postmarketing Experience With Paclitaxel Ebewe And Other Paclitaxel Ebewe Formulations
Unless otherwise noted, the following discussion refers to the adverse reactions that have been identified during post-approval use of Paclitaxel Ebewe. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. In some instances, severe events observed with Paclitaxel Ebewe injection may be expected to occur with Paclitaxel Ebewe.
Severe and sometimes fatal hypersensitivity reactions have been reported with Paclitaxel Ebewe. The use of Paclitaxel Ebewe in patients previously exhibiting hypersensitivity to Paclitaxel Ebewe injection or human albumin has not been studied.
There have been reports of congestive heart failure, left ventricular dysfunction, and atrioventricular block with Paclitaxel Ebewe. Most of the individuals were previously exposed to cardiotoxic drugs, such as anthracyclines, or had underlying cardiac history.
There have been reports of pneumonitis, interstitial pneumonia and pulmonary embolism in patients receiving Paclitaxel Ebewe and reports of radiation pneumonitis in patients receiving concurrent radiotherapy. Reports of lung fibrosis have been received as part of the continuing surveillance of Paclitaxel Ebewe injection safety and may also be observed with Paclitaxel Ebewe.
Cranial nerve palsies and vocal cord paresis have been reported, as well as autonomic neuropathy resulting in paralytic ileus.
Reports in the literature of abnormal visual evoked potentials in patients treated with Paclitaxel Ebewe injection suggest persistent optic nerve damage. These may also be observed with Paclitaxel Ebewe.
Reduced visual acuity due to cystoid macular edema (CME) has been reported during treatment with Paclitaxel Ebewe as well as with other taxanes. After cessation of treatment, CME improves and visual acuity may return to baseline.
Reports of hepatic necrosis and hepatic encephalopathy leading to death have been received as part of the continuing surveillance of Paclitaxel Ebewe injection safety and may occur following Paclitaxel Ebewe treatment.
There have been reports of intestinal obstruction, intestinal perforation, pancreatitis, and ischemic colitis following Paclitaxel Ebewe treatment. There have been reports of neutropenic enterocolitis (typhlitis), despite the coadministration of G-CSF, occurring in patients treated with Paclitaxel Ebewe injection alone and in combination with other chemotherapeutic agents.
Injection Site Reaction
There have been reports of extravasation of Paclitaxel Ebewe. Given the possibility of extravasation, it is advisable to monitor closely the Paclitaxel Ebewe infusion site for possible infiltration during drug administration.
Severe events such as phlebitis, cellulitis, induration, necrosis, and fibrosis have been reported as part of the continuing surveillance of Paclitaxel Ebewe injection safety. In some cases the onset of the injection site reaction in Paclitaxel Ebewe injection patients either occurred during a prolonged infusion or was delayed by a week to ten days. Recurrence of skin reactions at a site of previous extravasation following administration of Paclitaxel Ebewe injection at a different site, i.e., “recall”, has been reported.
Other Clinical Events
Skin reactions including generalized or maculopapular rash, erythema, and pruritus have been observed with Paclitaxel Ebewe. There have been case reports of photosensitivity reactions, radiation recall phenomenon, and in some patients previously exposed to capecitabine, reports of palmar-plantar erythrodysesthesia. Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
There have been reports of conjunctivitis, cellulitis, and increased lacrimation with Paclitaxel Ebewe injection.
No reports of accidental exposure to Paclitaxel Ebewe have been received. However, upon inhalation of Paclitaxel Ebewe, dyspnea, chest pain, burning eyes, sore throat, and nausea have been reported. Following topical exposure, events have included tingling, burning, and redness.
Paclitaxel Ebewe contraindications
Do not use Paclitaxel Ebewe if you are pregnant. It could harm the unborn baby.
You should not receive this medication if you are allergic to Paclitaxel Ebewe, or to other medications that contain an ingredient called Cremophor EL (polyoxyethylated castor oil). This includes cyclosporine (Gengraf, Neoral, Sandimmune) and teniposide (Vumon).
Before you receive Paclitaxel Ebewe, tell your doctor if you have HIV, AIDS, Kaposi's sarcoma, heart disease, high blood pressure, or liver disease.
There are many other medicines that can interact with Paclitaxel Ebewe. Tell your doctor about all other chemotherapy treatments you are receiving, and about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.
Paclitaxel Ebewe can lower blood cells that help your body fight infections and help your blood to clot. Your blood may need to be tested often. Avoid being near people who are sick or have infections. Avoid activities that may increase your risk of bleeding injury. Tell your doctor at once if you develop signs of infection.
Call your doctor if you have a serious side effect such as fever, flu symptoms, mouth sores, pale skin, easy bruising or bleeding, chest pain, trouble breathing, numbness or tingling, jaundice (yellowing of the skin or eyes), severe headache, buzzing in your ears, confusion, slow or uneven heartbeats, seizure (convulsions), or severe irritation where the medicine was injected.
Active ingredient matches for Paclitaxel Ebewe:
Paclitaxel in Belgium, Bulgaria, Croatia (Hrvatska), Czech Republic, Estonia, Finland, France, Georgia, Hungary, Latvia, Lithuania, Netherlands, New Zealand, Poland, Romania, Serbia, Slovenia, Sweden, Thailand, United States, Vietnam.
|Unit description / dosage (Manufacturer)||Price, USD|
|Paclitaxel Ebewe 6 mg/1 mL x 5 mL x 1 tube|
|Paclitaxel Ebewe 30 mg/5 mL x 1's|
|Paclitaxel Ebewe 100 mg/16.6 mL x 1's|
|Paclitaxel Ebewe 150 mg/25 mL x 1's|
|Paclitaxel Ebewe 210 mg/35 mL x 1's|
|Paclitaxel Ebewe 300 mg/50 mL x 1's|
|Paclitaxel Ebewe inj 100 mg/16.6 mL 1's (Sandoz)|
|Paclitaxel Ebewe inj 30 mg/5 mL 1's (Sandoz)|
|Paclitaxel Ebewe inj 300 mg/50 mL 1's (Sandoz)|
List of Paclitaxel Ebewe substitutes (brand and generic names):
|Paclitaxel-Teva 6 mg/ml (Hungary)|
|Paclitaxelum Accord (Poland)|
|Paclitaxelum Actavis (Vietnam)|
|Paclitaxelum Actavis 30 mg x 1 Bottle|
|Paclitaxelum Actavis 100 mg x 1 Bottle|
|Paclitaxelum Actavis 150 mg x 1 Bottle|
|Paclitaxelum Actavis 260 mg x 1 Bottle|
|Paclitaxelum Actavis 300 mg x 1 Bottle|
|Paclitaxelum Teva (Poland)|
|Paclitaxin (Belgium, Bulgaria, Finland, Netherlands, Philippines, Slovenia, Taiwan, Thailand)|
|Paclitaxin 6 mg/1 mL x 5 mL (Pharmachemie/Teva)|
|Paclitaxin 6 mg/1 mL x 16.7 mL (Pharmachemie/Teva)|
|Paclitaxin 6 mg/1 mL x 25 mL (Pharmachemie/Teva)|
|Paclitaxin 6 mg/1 mL x 50 mL (Pharmachemie/Teva)|
|Paclitaxin 30 mg/5 mL x 1's (Pharmachemie/Teva)|
|Paclitaxin 100 mg/16.7 mL x 1's (Pharmachemie/Teva)||$ 338.89|
|Paclitaxin 300 mg/50 mL x 1's (Pharmachemie/Teva)||$ 500.00|
|Paclitaxin / vial 30 mg/5 mL x 1's (Pharmachemie/Teva)||$ 100.00|
|Paclitaxin inj 100 mg/16.7 mL 1's (Pharmachemie/Teva)|
|Paclitaxin inj 30 mg/5 mL 1's (Pharmachemie/Teva)|
|Paclitaxin inj 300 mg/50 mL 1's (Pharmachemie/Teva)|
|Paclitaxin Concentrate (Singapore)|
|Paclitaxin Concentrate 6 mg/1 mL x 1's|
|Paclitec 30mg x 5mL VIAL / 1 (United Biotech)|
|Paclitec 100mg x 20mL VIAL / 1 (United Biotech)|
|Paclitec 260mg x 43.4mL VIAL / 1 (United Biotech)|
|30 mg x 5 mL x 1's (United Biotech)|
|100 mg x 20 mL x 1's (United Biotech)|
|260 mg x 43.4 mL x 1's (United Biotech)|
|PACLITEC 100MG INJECTION 1 vial / 20 ML injection each (United Biotech)||$ 66.14|
|PACLITEC inj 30 mg x 5 mL x 5ml (United Biotech)||$ 25.10|
|PACLITEC inj 100 mg x 20 mL x 20ml (United Biotech)||$ 66.35|
|PACLITEC inj 260 mg x 43.4 mL x 43.4ml (United Biotech)||$ 155.40|
|Paclitec 100mg Injection (United Biotech)||$ 3.31|
|Injectable; Injection; Paclitaxel 6 mg / ml|
|Pacliteva (Argentina, Bulgaria)|
|PACLITOL 100MG INJECTION 1 vial / 1 ML injection each (Pharmanel)||$ 21.58|
|PACLITOL 260MG INJECTION 1 vial / 1 ML injection each (Pharmanel)||$ 158.71|
|PACLITOL 30MG INJECTION 1 vial / 5 ML injection each (Pharmanel)||$ 33.33|
- DailyMed. "PACLITAXEL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "paclitaxel". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "paclitaxel". http://www.drugbank.ca/drugs/DB01229 (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Paclitaxel Ebewe are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Paclitaxel Ebewe. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
1 consumer reported usefulWas the Paclitaxel Ebewe drug useful in terms of decreasing the symptom or the disease?
According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology